Epstein Secrets

both the IPR decision and the lower court ruling can be appealed. Amanda Ens EFTA00820342 Director Bank of America Merrill Lynch Merrill Lynch, Pierce, Fenner & Smith Incorporated The power of global connectionsTM From: Ens, Amanda Sent: Wednesday, August 24, 2016 3:30 PM To: 'Richard Kahn' Subject: RE: TEVA...IPR Decision

for Ix Copaxone & is awaiting approval for 3TW. Sumant models $100mm/yr in sales for Copaxone for MYL (worth $1 to his DCF). For MNTA (partnered w/ Sandoz/NVS), they are a beneficiary of the IPRs (although not a party there) as they are part of the P-IV challenge which kicks off on 26-Sep (relates to 4 exi

both the IPR decision and the lower court ruling can be appealed. EFTA00820351 Amanda Ens Director Bank of America Merrill Lynch Merrill Lynch, Pierce, Fenner & Smith Incorporated The power of global connections"' From: Ens, Amanda Sent: Wednesday, August 24, 2016 3:30 PM To: 'Richard Kahn' Subject: RE: TEVA...IPR Decision

or lx Copaxone & is awaiting approval for 3TW. Sumant models $100mrn/yr in sales for Copaxone for MYL (worth $1 to his DCF). For MNTA (partnered w/ Sandoz/NVS), they are a beneficiary of the IPRs (although not a party there) as they are part of the P-IV challenge which kicks off on 26-Sep (relates to 4 exi

. We note that both the IPR decision and the lower court ruling can be appealed. Amanda Ens Director Bank of America Merrill Lynch Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park, 5th Floor, New York, NY 10036 Phone: Mobile: The power of global connectionsTM From: Ens, Amanda Sent: Wednesday, August 24, 2

for lx Copaxone & is awaiting approval for 3TW. Sumant models $100mm/yr in sales for Copaxone for MYL (worth $1 to his DCF). For MNTA (partnered w/ Sandoz/NVS), they are a beneficiary of the IPRs (although not a party there) as they are part of the P-IV challenge which kicks off on 26-Sep (relates to 4 exi